Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
If you own shares in Benitec Biopharma Limited (ASX:BLT) then it's worth thinking about how it contributes to the...
Anyone researching Benitec Biopharma Limited (NASDAQ:BNTC) might want to consider the historical volatility of the...
Benitec Biopharma (ASX: BLT, NASDAQ: BNTC) ("Benitec" or the "Company"), a biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced that in accordance with Australian Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the shareholder resolution to redomicile Benitec to the USA was passed.
NASDAQ:BNTCW) ("Benitec" or the "Company") announces it has entered into a securities purchase agreement ("SPA") with certain sophisticated and professional investors in the United States ("Investors") to issue 2,800,000 American Depositary Shares ("ADSs"), with each ADS representing 20 fully paid ordinary shares, at a purchase price of US$0.70 per ADS, in a registered direct offering. The Investors will also be issued warrants to purchase up to 412,863 ADSs in aggregate, at a purchase price per warrant equal to US$0.6999 per ADS to be issued on exercise of the warrant ("Pre-Funded Warrants"). The Pre-Funded Warrants may be exercised at any time from issue, in whole or in part, at an exercise price of US$0.0001 per ADS issued on exercise (subject to certain adjustments), provided that the beneficial ownership of the relevant Investor in the total number of ADSs on issue may not exceed 9.99%.
MELBOURNE, Australia , July 31, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing novel ...
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we...
MELBOURNE, Australia , Sept. 16, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary ...
If you want to know who really controls Benitec Biopharma Limited (ASX:BLT), then you'll have to look at the makeup of...
SYDNEY , June 6, 2019 /PRNewswire/ -- Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced the termination of the License and ...
Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) is pleased to announce its intention to redomicile from Australia to the United States of America. To implement the re-domiciliation, Benitec has entered into a Scheme Implementation Agreement dated 27 November 2019 with Benitec Biopharma Inc. ("Holdco"), a new US company incorporated for the purpose of effecting the re-domiciliation, pursuant to the terms of which Holdco will acquire all of the ordinary shares in Benitec ("Benitec Shares") and the warrants of Benitec listed on the Nasdaq Capital Markets ("Benitec Warrants") by way of two separate schemes of arrangement, pursuant to which:
Benitec Biopharma, Inc., a successor entity to Benitec Biopharma Limited (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced the appointment of Edward Smith to the Board of Directors.
Benitec Biopharma Limited (Benitec or the "Company") (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announce that the Supreme Court of Queensland ("Court") has approved the scheme of arrangement to redomicile the Benitec group from Australia to the United States of America.
Benitec Biopharma (ASX: BLT, NASDAQ: BNTC) ("Benitec" or the "Company"), a biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced its Appendix 4C for the quarter ending 31 December 2019.
MELBOURNE, Australia , Sept. 19, 2019 /PRNewswire/ -- Benitec Biopharma Ltd (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary ...
Benitec Biopharma Inc. (NASDAQ: BNTC) is pleased to announce that the previously announced transaction to redomicile from Australia to the United States has been fully implemented today. The redomiciliation was approved by Benitec shareholders at a Scheme Meeting held on March 26, 2020, and confirmed by the Supreme Court of Queensland on March 30, 2020.